With an objective of not giving any such scope for price escalation as Martin Shkreli did for Daraprim generic drug, US Food and Drug Administration (US FDA) has turned very cautious on approvals to generic drugs. US FDA is now reviewing new applications for generic drugs, while ensuring no such lapses of price escalation.
new applications
Breaking News
Subscribe to VCpost newsletter
Most Popular
- SSI Payment for May 2024: Supplemental Security Income Recipients to See Double Amount in Payout
- IBM Set to Acquire HashiCorp in Possible Mega-Deal, Stock Skyrockets 24% to $6.1 Billion Valuation
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- Samsung to Implement Six-Day Work Week for Executives Slammed by Critics 'Not Effective'
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- US Chamber of Commerce Vows to Sue FTC's Noncompete Agreement Ban; Calls Rule 'Unlawful Power Grab'
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- Philippines Wants US, Japan to Fund Freight Railway Project After It Drops Funding Talks With China